Latest news with #Dr.Reddy's
Business Upturn
3 days ago
- Business
- Business Upturn
Nifty 50 top losers today, June 20: Bajaj Auto, Hero MotoCorp, Dr. Reddy's, Maruti Suzuki and more
By Aman Shukla Published on June 20, 2025, 15:44 IST Indian stock markets ended the trading session on a high note on June 20, with benchmark indices surging to high levels. The Nifty 50 crossed the 25,000 mark, closing at 25,112.40, up by 319.15 points (1.29%). The BSE Sensex also witnessed a strong rally, rising 1,046.30 points (1.29%) to settle at 82,408.17. Despite the market's overall bullish trend, several heavyweight stocks saw significant declines during the session. Among the biggest losers of the day were well-known names like Bajaj Auto, Hero MotoCorp and Dr. Reddy's. Let's take a closer look at the top losers of the Nifty 50, according to Trendlyne. Nifty 50 top losers on June 20 Bajaj Auto was the top loser, closing 1.8% lower at ₹8,345. Hero MotoCorp ended the session down by 1.2%, settling at ₹4,331.1. Dr. Reddy's declined 0.3% to close at ₹1,322.8. Maruti Suzuki slipped 0.2% and ended at ₹12,787. ONGC registered a marginal drop of 0.1%, closing at ₹251.2. Axis Bank also fell 0.1% to finish at ₹1,216.1. Infosys ended flat, closing unchanged at ₹1,618. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Bajaj AutoDr Reddy'sHero MotocorpMaruti SuzukiNifty Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
6 days ago
- Business
- Business Upturn
Pharma stocks in focus as Trump announces tariffs on sector ‘soon'
Indian pharmaceutical stocks are in focus today after U.S. President Donald Trump announced that pharma tariffs are coming very soon. According to industry data, companies with the highest U.S. revenue exposure include Alembic Pharma (50%+), Aurobindo Pharma (45%+), and Dr. Reddy's and Zydus (both 40%). These firms are likely to be the most impacted if tariffs are introduced or raised on pharmaceutical imports from India. Here's a quick look at U.S. revenue exposure for key Indian pharma companies: Company % Revenue from U.S. Alembic 50%+ Aurobindo 45%+ Dr. Reddy's 40% Zydus 40% Lupin 34–38% Sun Pharma 30–35% Glenmark 30% Cipla 25–30% Torrent ~15–20% Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Economic Times
06-06-2025
- Business
- Economic Times
Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Dr. Reddy's Laboratories rose 1.4% to touch the day's high of Rs 1,307.65 on the BSE on Friday, June 6, after the company announced a strategic collaboration with Alvotech , a global biotech firm, to co-develop and commercialize a biosimilar candidate to Keytruda ( pembrolizumab ) for global markets.'Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, and Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets,' Dr. Reddy's said in an exchange a leading immunotherapy drug used in the treatment of various cancers, generated $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars partnership represents a significant opportunity for Dr. Reddy's to enter the high-value biosimilar segment for oncology drugs, a category that continues to witness growing demand and heightened competitive the agreement, both parties will jointly develop and manufacture the biosimilar, sharing costs and responsibilities. Importantly, each company will retain the right to commercialize the product globally, subject to certain deal is expected to accelerate development timelines and expand the global market reach of the biosimilar.Róbert Wessman, Chairman and CEO of Alvotech, emphasized that the agreement will help deliver cost-effective, critical biologic medicines to patients worldwide by combining Dr. Reddy's commercial strength with Alvotech's R&D and manufacturing this collaboration, Dr. Reddy's further strengthens its pipeline in the biosimilars segment.'We are pleased to collaborate with Alvotech on the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high-quality, affordable treatment options for patients across the world. Oncology has been a key focus area for us, and this collaboration will enhance our capabilities in this domain, as pembrolizumab represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy' Reddy's Laboratories shares ended Thursday's session higher by 3% at Rs 1,289.90 on BSE.
Time of India
06-06-2025
- Business
- Time of India
Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Shares of Dr. Reddy's Laboratories rose 1.4% to touch the day's high of Rs 1,307.65 on the BSE on Friday, June 6, after the company announced a strategic collaboration with Alvotech , a global biotech firm, to co-develop and commercialize a biosimilar candidate to Keytruda ( pembrolizumab ) for global markets. 'Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, and Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets,' Dr. Reddy's said in an exchange filing. Keytruda, a leading immunotherapy drug used in the treatment of various cancers, generated $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars market. This partnership represents a significant opportunity for Dr. Reddy's to enter the high-value biosimilar segment for oncology drugs, a category that continues to witness growing demand and heightened competitive activity. Under the agreement, both parties will jointly develop and manufacture the biosimilar, sharing costs and responsibilities. Importantly, each company will retain the right to commercialize the product globally, subject to certain exceptions. The deal is expected to accelerate development timelines and expand the global market reach of the biosimilar. Róbert Wessman, Chairman and CEO of Alvotech, emphasized that the agreement will help deliver cost-effective, critical biologic medicines to patients worldwide by combining Dr. Reddy's commercial strength with Alvotech's R&D and manufacturing expertise. With this collaboration, Dr. Reddy's further strengthens its pipeline in the biosimilars segment. 'We are pleased to collaborate with Alvotech on the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high-quality, affordable treatment options for patients across the world. Oncology has been a key focus area for us, and this collaboration will enhance our capabilities in this domain, as pembrolizumab represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's. Dr. Reddy's Laboratories shares ended Thursday's session higher by 3% at Rs 1,289.90 on BSE. Also read: Positive Breakout: These 5 stocks cross above their 200 DMAs ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Business Upturn
05-06-2025
- Business
- Business Upturn
Nifty 50 top gainers today, June 5: Eternal, Trent, Dr. Reddy's, Power Grid, ICICI Bank and more
By Aman Shukla Published on June 5, 2025, 15:40 IST Indian equity markets continued their upward momentum on June 5, with the Nifty 50 closing above the 24,750 level. The Sensex gained 443.79 points, or 0.55%, to close at 81,442.04, while the Nifty 50 rose by 130.70 points, or 0.53%, ending the day at 24,750.90. Among the Nifty 50 stocks, several companies recorded significant gains, led by Eternal, Trent and Dr. Reddy's. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day. Nifty 50 Top Gainers on June 5 Eternal gained 4.4% and closed at ₹256.6. Trent rose 3.2% to close at ₹5680.0. Dr. Reddy's Laboratories increased by 3.1%, closing at ₹1290.1. Power Grid Corporation went up 2.0% to close at ₹294.3. ICICI Bank added 1.7%, ending the day at ₹1454.8. Shriram Finance rose 1.6%, closing at ₹651.5. UltraTech Cement advanced 1.3% to ₹11180.0. Reliance Industries gained 1.3%, closing at ₹1442.4. Cipla increased by 1.2%, with a close of ₹1490.0. Adani Ports & Special Economic Zone rose 1.2% to ₹1453.0. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Dr Reddy'sEternalICICI BankNifty 50Power GridTrent Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
